{"id":"NCT00491491","sponsor":"Sheba Medical Center","briefTitle":"Zevalin-beam for Aggressive Lymphoma","officialTitle":"SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2007-06-26","resultsPosted":"2020-08-31","lastUpdate":"2020-08-31"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin's Lymphoma"],"interventions":[{"type":"DRUG","name":"ibritumomab tiuxetan","otherNames":["zevalin"]},{"type":"PROCEDURE","name":"BEAM chemotherapy and autologous stem-cell transplantation","otherNames":[]}],"arms":[{"label":"Z-BEAM","type":"EXPERIMENTAL"},{"label":"standard BEAM","type":"ACTIVE_COMPARATOR"}],"summary":"The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.","primaryOutcome":{"measure":"Overall Survival","timeFrame":"2 years after transplantation","effectByArm":[{"arm":"Z-BEAM","deltaMin":91,"sd":null},{"arm":"Standard BEAM","deltaMin":62,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":9,"countries":["United States","Germany","Israel","Netherlands"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":22},"commonTop":["infection"]}}